Structure Therapeutics has announced encouraging clinical trial results across two of its lead programs in chronic weight management: ACCG‑2671, an oral small molecule amylin receptor agonist, and aleniglipron, an oral GLP‑1 receptor agonist. The company says the findings strengthen its position in the race to deliver convenient, scalable alternatives to injectable peptide therapies.
ACCG‑2671: First Oral Amylin Agonist Shows Early Promise
In a Phase 1/2a single ascending dose study, ACCG‑2671 demonstrated a long half‑life of about six days, supporting potential once‑weekly dosing. No serious adverse events were reported, and exploratory findings showed target engagement, including a 3.3% mean reduction in body weight after a single dose. The compound also reduced CTX‑1, a biomarker of bone resorption, by roughly 60%.
Structure has now begun dosing participants in the multiple ascending dose portion of the trial, which will run for 12 weeks and include obese participants. Topline data are expected in the first half of 2027. The company is also testing ACCG‑2671 in combination with injectable GLP‑1 agonists to assess potential synergy.
Aleniglipron: Durable Weight Loss Without Plateau
The ACCESS open‑label extension trial reported up to 16.2% mean body weight loss at 72 weeks for participants on aleniglipron, with no evidence of plateau. More than one‑third of patients in the highest dose groups achieved over 20% weight reduction, translating to 35–40 pounds lost on average. Importantly, fewer than 5% discontinued treatment due to adverse events, and tolerability improved when participants began with a lower 2.5 mg starting dose.
Aleniglipron is now being evaluated in the Phase 3 ACCOMPLISH program, which will enroll more than 4,700 adults across two trials. Topline data are expected in the second half of 2028.
Why It Matters
Amylin and GLP‑1 are both peptide hormones central to appetite and weight regulation. Structure’s strategy is to mimic these pathways with non‑peptide small molecules, aiming to deliver the same metabolic benefits in a pill form. If successful, oral therapies could broaden access, reduce costs, and compete directly with injectable peptide drugs like semaglutide.
The company’s dual progress — early signals from ACCG‑2671 and durable efficacy from aleniglipron — positions it as a serious contender in the next wave of obesity treatments.
Related Coverage: For more on peptide‑linked metabolic therapies facing regulatory hurdles, see our coverage of Aardvark Therapeutics Class Action.